相似文献
1
Emerging therapies for breast cancer.
J Hematol Oncol. 2017 Apr 28;10(1):98. doi: 10.1186/s13045-017-0466-3.
2
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Oncologist. 2017 Sep;22(9):1028-1038. doi: 10.1634/theoncologist.2017-0072. Epub 2017 Jun 26.
3
Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.
EBioMedicine. 2024 Jul;105:105186. doi: 10.1016/j.ebiom.2024.105186. Epub 2024 Jun 10.
4
Recent advances of highly selective CDK4/6 inhibitors in breast cancer.
J Hematol Oncol. 2017 Apr 24;10(1):97. doi: 10.1186/s13045-017-0467-2.
5
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer.
Eur J Clin Invest. 2021 Jul;51(7):e13535. doi: 10.1111/eci.13535. Epub 2021 Mar 16.
6
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
Clin Cancer Res. 2016 Oct 15;22(20):4968-4972. doi: 10.1158/1078-0432.CCR-16-0493. Epub 2016 Jul 12.
7
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Lancet Oncol. 2019 Oct;20(10):1360-1369. doi: 10.1016/S1470-2045(19)30420-6. Epub 2019 Sep 4.
8
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
N Engl J Med. 2015 Jul 16;373(3):209-19. doi: 10.1056/NEJMoa1505270. Epub 2015 Jun 1.
9
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Clin Cancer Res. 2015 Nov 15;21(22):5121-5130. doi: 10.1158/1078-0432.CCR-15-0360. Epub 2015 May 19.
10
Palbociclib Extends Survival in Advanced Breast Cancer.
Cancer Discov. 2015 Jul;5(7):OF5. doi: 10.1158/2159-8290.CD-NB2015-083. Epub 2015 Jun 2.
引用本文的文献
1
Integrating scRNA-seq and spatial transcriptomics to explore the implication of G6PD on immune microenvironment in lymphatic metastasis of breast cancer.
Med Oncol. 2025 Jul 21;42(8):355. doi: 10.1007/s12032-025-02943-7.
2
Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.
Front Oncol. 2025 Jan 9;14:1515387. doi: 10.3389/fonc.2024.1515387. eCollection 2024.
3
Mechanisms of endocrine resistance in hormone receptor-positive breast cancer.
Front Oncol. 2024 Oct 31;14:1448687. doi: 10.3389/fonc.2024.1448687. eCollection 2024.
4
Recent advances in the strategic incorporation of fluorine into new-generation taxoid anticancer agents.
J Fluor Chem. 2023 Apr;267. doi: 10.1016/j.jfluchem.2023.110106. Epub 2023 Feb 21.
5
A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022.
Front Oncol. 2024 Jun 4;14:1366900. doi: 10.3389/fonc.2024.1366900. eCollection 2024.
6
Circulating tumor DNA: from discovery to clinical application in breast cancer.
Front Immunol. 2024 Apr 30;15:1355887. doi: 10.3389/fimmu.2024.1355887. eCollection 2024.
7
Exploring Phytochemicals as Potential Inhibitors for Breast Cancer Genes BRCA1 and BRCA2 Using Pharmacophore Modeling, Molecular Docking, MD Simulations, and DFT Analysis.
ACS Omega. 2024 Jan 3;9(2):2161-2182. doi: 10.1021/acsomega.3c05098. eCollection 2024 Jan 16.
8
Cell-cell communication characteristics in breast cancer metastasis.
Cell Commun Signal. 2024 Jan 19;22(1):55. doi: 10.1186/s12964-023-01418-4.
9
Zinc-finger protein 382 antagonises CDC25A and ZEB1 signaling pathway in breast cancer.
Genes Dis. 2022 Feb 9;10(2):568-582. doi: 10.1016/j.gendis.2021.12.019. eCollection 2023 Mar.
10
Advances in CAR-T Cell Therapy in Head and Neck Squamous Cell Carcinoma.
J Clin Med. 2023 Mar 10;12(6):2173. doi: 10.3390/jcm12062173.
本文引用的文献
1
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Ann Oncol. 2018 Aug 1;29(8):1763-1770. doi: 10.1093/annonc/mdy201.
2
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
JAMA Oncol. 2018 Mar 1;4(3):302-308. doi: 10.1001/jamaoncol.2017.4612.
3
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline mutation demonstrates marked activity.
NPJ Breast Cancer. 2017 Dec 6;3:49. doi: 10.1038/s41523-017-0052-4. eCollection 2017.
4
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Breast Cancer Res Treat. 2018 Feb;167(3):671-686. doi: 10.1007/s10549-017-4537-5. Epub 2017 Oct 23.
5
-Paclitaxel for the treatment of breast cancer: an update across treatment settings.
Exp Hematol Oncol. 2017 Mar 22;6:7. doi: 10.1186/s40164-017-0066-5. eCollection 2017.
6
A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline -Mutated Ovarian Carcinoma or Other Solid Tumors.
Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.
7
New development in CAR-T cell therapy.
J Hematol Oncol. 2017 Feb 21;10(1):53. doi: 10.1186/s13045-017-0423-1.
8
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
Lancet Oncol. 2017 Mar;18(3):371-383. doi: 10.1016/S1470-2045(17)30088-8. Epub 2017 Feb 11.
9
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Lancet Oncol. 2017 Feb;18(2):212-220. doi: 10.1016/S1470-2045(17)30007-4. Epub 2017 Jan 10.
10
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study.
J Clin Oncol. 2017 Jan 10;35(2):141-148. doi: 10.1200/JCO.2016.67.4887. Epub 2016 Nov 7.
Zotero 插件